RLY-4008 (lirafugratinib)
FGFR2-altered solid tumors (e.g., cholangiocarcinoma)
Key Facts
Indication
FGFR2-altered solid tumors (e.g., cholangiocarcinoma)
Phase
Phase 1/2
Status
Active
Company
About Relay Therapeutics
Relay Therapeutics is redefining drug discovery by focusing on the dynamic nature of proteins, moving beyond static structures to understand how protein motion influences function and disease. Its proprietary Dynamo platform combines computational structural biology, machine learning, and experimental techniques to identify novel drug targets and allosteric sites. The company has advanced a pipeline of precision oncology candidates, most notably RLY-4008, a highly selective FGFR2 inhibitor, and is building a robust portfolio targeting validated oncogenes with next-generation specificity. Relay's approach aims to create best-in-class therapies with improved safety and efficacy profiles.
View full company profile